The development of GLP-1 agonists and other therapies for weight loss and obesity is evolving and so is the advancement of imaging biomarkers for body composition profiling. The options to delineate and quantify muscle and lean mass are getting more sophisticated, so determining which imaging modality, anatomical coverage, and analysis methods to use can be critical to your obesity clinical trial outcomes.
Perceptive Imaging combines the right experience and the right people to help you navigate the nuances of imaging in weight loss clinical trials and to drive the success of your development program.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
